EP1734986A4 - Procede pour la modulation de l'appetit - Google Patents

Procede pour la modulation de l'appetit

Info

Publication number
EP1734986A4
EP1734986A4 EP05729508A EP05729508A EP1734986A4 EP 1734986 A4 EP1734986 A4 EP 1734986A4 EP 05729508 A EP05729508 A EP 05729508A EP 05729508 A EP05729508 A EP 05729508A EP 1734986 A4 EP1734986 A4 EP 1734986A4
Authority
EP
European Patent Office
Prior art keywords
appetit
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05729508A
Other languages
German (de)
English (en)
Other versions
EP1734986A1 (fr
EP1734986B1 (fr
Inventor
Samuel Norbert Breit
Asne Rhoda Bauskin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Vincent's Hospital Sydney
Original Assignee
St Vincent's Hospital Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1734986(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Priority to EP15163748.5A priority Critical patent/EP2929891B1/fr
Priority to DK11183884.3T priority patent/DK2441466T3/da
Application filed by St Vincent's Hospital Sydney filed Critical St Vincent's Hospital Sydney
Priority to PL15163748T priority patent/PL2929891T3/pl
Priority to EP11183884.3A priority patent/EP2441466B1/fr
Priority to EP14171119.2A priority patent/EP2774620A1/fr
Priority to PL11183884T priority patent/PL2441466T3/pl
Priority to DK15163748.5T priority patent/DK2929891T3/da
Publication of EP1734986A1 publication Critical patent/EP1734986A1/fr
Publication of EP1734986A4 publication Critical patent/EP1734986A4/fr
Publication of EP1734986B1 publication Critical patent/EP1734986B1/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP05729508.1A 2004-04-13 2005-04-13 Procede pour la modulation de l'appetit Expired - Lifetime EP1734986B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten
EP15163748.5A EP2929891B1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de l'appétit
PL15163748T PL2929891T3 (pl) 2004-04-13 2005-04-13 Sposób modulowania apetytu
EP11183884.3A EP2441466B1 (fr) 2004-04-13 2005-04-13 Agent inhibiteur de MIC-1
EP14171119.2A EP2774620A1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de perte de poids
PL11183884T PL2441466T3 (pl) 2004-04-13 2005-04-13 Środek hamujący MIC-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
PCT/AU2005/000525 WO2005099746A1 (fr) 2004-04-13 2005-04-13 Procede pour la modulation de l'appetit

Related Child Applications (6)

Application Number Title Priority Date Filing Date
EP14171119.2A Division EP2774620A1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de perte de poids
EP14171119.2A Division-Into EP2774620A1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de perte de poids
EP11183884.3A Division-Into EP2441466B1 (fr) 2004-04-13 2005-04-13 Agent inhibiteur de MIC-1
EP11183884.3A Division EP2441466B1 (fr) 2004-04-13 2005-04-13 Agent inhibiteur de MIC-1
EP15163748.5A Division EP2929891B1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de l'appétit
EP15163748.5A Division-Into EP2929891B1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de l'appétit

Publications (3)

Publication Number Publication Date
EP1734986A1 EP1734986A1 (fr) 2006-12-27
EP1734986A4 true EP1734986A4 (fr) 2009-07-22
EP1734986B1 EP1734986B1 (fr) 2015-11-11

Family

ID=35149777

Family Applications (4)

Application Number Title Priority Date Filing Date
EP11183884.3A Expired - Lifetime EP2441466B1 (fr) 2004-04-13 2005-04-13 Agent inhibiteur de MIC-1
EP14171119.2A Withdrawn EP2774620A1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de perte de poids
EP15163748.5A Expired - Lifetime EP2929891B1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de l'appétit
EP05729508.1A Expired - Lifetime EP1734986B1 (fr) 2004-04-13 2005-04-13 Procede pour la modulation de l'appetit

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP11183884.3A Expired - Lifetime EP2441466B1 (fr) 2004-04-13 2005-04-13 Agent inhibiteur de MIC-1
EP14171119.2A Withdrawn EP2774620A1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de perte de poids
EP15163748.5A Expired - Lifetime EP2929891B1 (fr) 2004-04-13 2005-04-13 Procédé de modulation de l'appétit

Country Status (11)

Country Link
US (7) US8192735B2 (fr)
EP (4) EP2441466B1 (fr)
JP (4) JP5448338B2 (fr)
CA (2) CA2905125C (fr)
CY (1) CY1115731T1 (fr)
DK (2) DK2441466T3 (fr)
ES (3) ES2555956T3 (fr)
PL (2) PL2441466T3 (fr)
PT (2) PT2441466E (fr)
SI (1) SI2441466T1 (fr)
WO (1) WO2005099746A1 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2441466T3 (da) * 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) * 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
CA2740632A1 (fr) * 2008-10-31 2010-05-06 St. Vincent's Hospital Sydney Limited Procede de pronostic d'une affection renale chronique
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
CA2899170C (fr) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions et methodes d'utilisation servant au traitement de desordres metaboliques
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT3027642T (lt) 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
CA2952032C (fr) * 2014-06-20 2023-03-14 Aveo Pharmaceuticals, Inc. Traitement d'une maladie renale chronique et d'autres dysfonctionnements renaux au moyen d'un modulateur gdf15
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN106573955B (zh) * 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
WO2015197446A1 (fr) 2014-06-24 2015-12-30 Novo Nordisk A/S Protéines de fusion mic-1 et leurs utilisations
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
EP3851122A1 (fr) * 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Procédés d'inversion de la cachexie et de prolongation de la survie, comprenant l'administration d'un modulateur de gdf15 et d'un agent anticancéreux
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
WO2016102580A1 (fr) * 2014-12-22 2016-06-30 Novo Nordisk A/S Protéines de fusion alpha-1-antitrypsine (a1at) et leurs utilisations
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR102722730B1 (ko) 2015-10-02 2024-10-25 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
EP3356827B1 (fr) 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 comme marqueur de diagnostic pour prévoir le résultat clinique d'un traitement avec des inhibiteurs de contrôle immunés
WO2017121865A1 (fr) 2016-01-15 2017-07-20 Novo Nordisk A/S Récepteur de mic-1 et utilisations correspondantes
JP6829444B2 (ja) * 2016-02-29 2021-02-10 公立大学法人横浜市立大学 去勢抵抗性前立腺癌を検出する方法及び検出試薬
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
WO2018071493A1 (fr) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Procédés de criblage de modulateurs d'une activité biologique de type gdf15
EP3551214B1 (fr) 2016-12-06 2024-03-13 St Vincent's Hospital Sydney Limited Traitement de l'obésité et des troubles alimentaires
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (fr) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Anticorps se liant spécifiquement à une protéine mic-1, et utilisation associée
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
US12054527B2 (en) 2018-04-09 2024-08-06 Amgen Inc. Growth differentiation factor 15 fusion proteins
CN112912395B (zh) 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法
US11810670B2 (en) 2018-11-13 2023-11-07 CurieAI, Inc. Intelligent health monitoring
ES3061099T3 (en) 2019-10-04 2026-03-31 Amgen Inc Use of gdf15 for treating cardiometabolic syndrome and other conditions
CA3161302A1 (fr) 2019-11-26 2021-06-03 Yuhan Corporation Proteine de fusion gdf15 a action prolongee et composition pharmaceutique la comprenant
WO2021111636A1 (fr) 2019-12-06 2021-06-10 大塚製薬株式会社 Anticorps anti-gdf15
LT4243928T (lt) 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui
WO2022207846A1 (fr) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Inhibiteurs thérapeutiques de la signalisation gdf15
EP4351627A4 (fr) 2021-05-21 2025-06-04 Yuhan Corporation Composition pour polythérapie comprenant un variant de facteur de différenciation de croissance 15 et un agoniste du récepteur du peptide 1 de type glucagon
AU2022278933A1 (en) 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (fr) 2021-12-22 2023-06-29 Byomass Inc. Ciblage d'une référence croisée de la voie gdf15-gfral vers applications associées
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (fr) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Facteur de differenciation en cours de croissance 15
WO2001081928A1 (fr) * 2000-04-20 2001-11-01 St Vincent's Hospital Sydney Limited Methode diagnostique et procede de traitement impliquant la cytokine-1 inhibitrice macrophage (mic-1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE423788T1 (de) 1995-06-22 2009-03-15 St Vincents Hosp Sydney Neues tgf-beta-ahnliches cytokin
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US7141661B2 (en) * 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
CA2390820A1 (fr) * 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methodes de diagnostic, de pronostic et de traitement de maladies cardiovasculaires
DK2441466T3 (da) * 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
ES2428869T3 (es) * 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (fr) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Facteur de differenciation en cours de croissance 15
WO2001081928A1 (fr) * 2000-04-20 2001-11-01 St Vincent's Hospital Sydney Limited Methode diagnostique et procede de traitement impliquant la cytokine-1 inhibitrice macrophage (mic-1)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HARRY RUBIN: "Cancer cachexia: Its correlations and causes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 100, no. 9, 29 April 2003 (2003-04-29), pages 5384 - 5389, XP009117770, ISSN: 0027-8424 *
See also references of WO2005099746A1 *
WELSH J B ET AL: "Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 100, no. 6, 18 March 2003 (2003-03-18), pages 3410 - 3415, XP002993660, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CY1115731T1 (el) 2017-01-25
CA2561877C (fr) 2017-03-14
JP2013209376A (ja) 2013-10-10
ES2788868T3 (es) 2020-10-23
US8192735B2 (en) 2012-06-05
EP2774620A1 (fr) 2014-09-10
PL2929891T3 (pl) 2020-08-24
JP2011190262A (ja) 2011-09-29
EP1734986A1 (fr) 2006-12-27
PT2441466E (pt) 2014-09-09
JP5448338B2 (ja) 2014-03-19
JP5806275B2 (ja) 2015-11-10
US8946146B2 (en) 2015-02-03
CA2561877A1 (fr) 2005-10-27
US20180346560A1 (en) 2018-12-06
WO2005099746A1 (fr) 2005-10-27
US20210340243A1 (en) 2021-11-04
US20160289320A1 (en) 2016-10-06
DK2929891T3 (da) 2020-05-11
DK2441466T3 (da) 2014-10-27
US20150183861A1 (en) 2015-07-02
US20090004181A1 (en) 2009-01-01
SI2441466T1 (sl) 2015-01-30
EP2929891A1 (fr) 2015-10-14
PT2929891T (pt) 2020-04-08
JP2014051511A (ja) 2014-03-20
US20110123454A1 (en) 2011-05-26
US20250109192A1 (en) 2025-04-03
ES2518865T3 (es) 2014-11-05
PL2441466T3 (pl) 2015-01-30
HK1168274A1 (en) 2012-12-28
CA2905125C (fr) 2017-02-07
HK1215932A1 (en) 2016-09-30
CA2905125A1 (fr) 2005-10-27
JP2007532586A (ja) 2007-11-15
EP1734986B1 (fr) 2015-11-11
EP2441466A1 (fr) 2012-04-18
EP2441466B1 (fr) 2014-07-23
ES2555956T3 (es) 2016-01-11
JP5767667B2 (ja) 2015-08-19
EP2929891B1 (fr) 2020-03-11

Similar Documents

Publication Publication Date Title
FR2882998B1 (fr) Procede pour l'obtention de cristaux de carbonate de sodium
EP1588708A4 (fr) Procede pour realiser une preparation enrobee
EP2049710A4 (fr) Electrode de reference et procede pour la produire
FR2873685B1 (fr) Procede d'obtention de ceramiques poreuses
FR2842200B1 (fr) Procede pour l'obtention de polysaccharides modifies
EP1937312A4 (fr) Composés oligomériques chimériques pour la modulation de l'epissage
EP1934969A4 (fr) Procede d'eclairage pour l'affichage de schemas graphiques
MA28721B1 (fr) Procede d'application de pesticides
EP1710836A4 (fr) Procede pour la fabrication de tranches soi
EP1842048A4 (fr) Procede d'amelioration de l'image en fluorescence
FR2881732B1 (fr) Procede pour la purification de chlorure d'hydrogene
FR2837385B1 (fr) Procede d'obtention de phytoalexines
FR2925352B1 (fr) Procede de greffage d'un element poreux pour la deleucocytation
EP1755596A4 (fr) Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes
EP1757933A4 (fr) Procédé pour la détermination de l'odeur corporelle
FR2872374B1 (fr) Coffret intelligent pour l'exterieur
EP1692150A4 (fr) Procede de preparation de diphosphures de pentaerythrite
EP1813700A4 (fr) Appareil pour la production de cristaux
EP1847624A4 (fr) NOUVEL ALLIAGE DE Fe-Al ET PROCEDE POUR LE PRODUIRE
EP1740923A4 (fr) Procede de compensation d'hysterese
EP1705704A4 (fr) Procede de production d'une plaquette soi
EP1849763A4 (fr) Procede pour la synthese de methacrylate de tert-butyle
FR2846977B1 (fr) Procede pour ameliorer la qualite de non tisses
EP1743953A4 (fr) Procede de formation d'un film de cuivre
EP1629833A4 (fr) Procede pour produire des microparticules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1099212

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAUSKIN, ASNE RHODA

Inventor name: BREIT, SAMUEL NORBERT

A4 Supplementary search report drawn up and despatched

Effective date: 20090622

17Q First examination report despatched

Effective date: 20091005

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150528

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 760113

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005047883

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2555956

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20160111

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 760113

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160311

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005047883

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: MAIWALD PATENTANWALTS GMBH

Effective date: 20160811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160413

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160413

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1099212

Country of ref document: HK

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050413

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

R26 Opposition filed (corrected)

Opponent name: MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Effective date: 20160811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 602005047883

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20200515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602005047883

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240313

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240409

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240405

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240501

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240513

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240419

Year of fee payment: 20

Ref country code: FR

Payment date: 20240408

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240409

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602005047883

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20250412

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20250425

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20250412

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20250413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20250412

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20250414